Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Natural killer (NK) cell and dendritic cell (DC) interface represents a complex bidirectional crosstalk essential for the coordination of innate and adaptive immune responses (Degli-Esposti & Smyth, 2005, Nature Reviews Immunology). This interaction occurs primarily in secondary lymphoid organs and peripheral tissues, where DCs activate NK cells through the secretion of cytokines such as IL-12, IL-15, and IL-18, and through direct contact via surface molecules (Ferlazzo & Morandi, 2014, Frontiers in Immunology). Conversely, NK cells promote DC maturation and Th1 polarization by producing interferon-gamma (IFN-γ) and tumor necrosis factor (TNF). A unique aspect of this interface is "DC editing," where NK cells selectively eliminate immature DCs via the NKp30 receptor to ensure only high-quality antigen-presenting cells initiate T-cell responses (Pallmer & Oxenius, 2016, Frontiers in Immunology). Dysregulation of this interface is implicated in cancer progression, where the crosstalk is often suppressed, and in autoimmune diseases where it may be overactive. Therapeutic strategies aim to harness this interface by using recombinant cytokines or monoclonal antibodies to enhance the anti-tumor activity of the NK-DC axis (Ferlazzo & Morandi, 2014, Frontiers in Immunology).
Modulation of bidirectional signaling between NK cells and DCs to enhance immune surveillance and effector function.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer cell and dendritic cell interface (NK-DC interface).